Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies.

Sohma H, Imai S, Takei N, Honda H, Matsumoto K, Utsumi K, Matsuki K, Hashimoto E, Saito T, Kokai Y.

Front Aging Neurosci. 2013 Apr 5;5:15. doi: 10.3389/fnagi.2013.00015. eCollection 2013.

2.

Apolipoprotein E4 frequencies in a Japanese population with Alzheimer's disease and dementia with Lewy bodies.

Kobayashi S, Tateno M, Park TW, Utsumi K, Sohma H, Ito YM, Kokai Y, Saito T.

PLoS One. 2011 Apr 28;6(4):e18569. doi: 10.1371/journal.pone.0018569.

3.

Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort.

Berge G, Sando SB, Rongve A, Aarsland D, White LR.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1227-31. doi: 10.1136/jnnp-2013-307228. Epub 2014 Mar 17.

4.

Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.

Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.

J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.

PMID:
26923009
5.

Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies.

Singleton AB, Wharton A, O'Brien KK, Walker MP, McKeith IG, Ballard CG, O'Brien J, Perry RH, Ince PG, Edwardson JA, Morris CM.

Dement Geriatr Cogn Disord. 2002;14(4):167-75.

PMID:
12411758
6.
7.

Investigation of annexin A5 as a biomarker for Alzheimer's disease using neuronal cell culture and mouse model.

Yamaguchi M, Kokai Y, Imai S, Utsumi K, Matsumoto K, Honda H, Mizue Y, Momma M, Maeda T, Toyomasu S, Ito YM, Kobayashi S, Hashimoto E, Saito T, Sohma H.

J Neurosci Res. 2010 Sep;88(12):2682-92. doi: 10.1002/jnr.22427.

PMID:
20648654
8.

CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.

Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.

J Neurochem. 2013 Dec;127(5):681-90. doi: 10.1111/jnc.12331. Epub 2013 Jun 26.

9.

[Apolipoprotein E4 in dementia with Lewy bodies].

Carrillo García F, Gil Néciga E, Alberca R, García-Solís D, Millán J, Rodríguez Uranga JJ, Franco E, Mir P, Suárez A, García R, Serrano-Pozo A, Pérez-Díaz H, Polo J.

Neurologia. 2008 Apr;23(3):152-6. Spanish.

PMID:
18370334
10.

Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.

Herbert MK, Aerts MB, Kuiperij HB, Claassen JA, Spies PE, Esselink RA, Bloem BR, Verbeek MM.

Alzheimers Dement. 2014 Jul;10(4):448-55.e2. doi: 10.1016/j.jalz.2013.05.1775. Epub 2013 Nov 13.

PMID:
24239248
11.

Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer's disease and in dementia with Lewy bodies. Distinctions between diseases.

Lamb H, Christie J, Singleton AB, Leake A, Perry RH, Ince PG, McKeith IG, Melton LM, Edwardson JA, Morris CM.

Neurology. 1998 Feb;50(2):388-91.

PMID:
9484359
12.

Dementia with Lewy bodies and Alzheimer's disease.

Rosenberg CK, Cummings TJ, Saunders AM, Widico C, McIntyre LM, Hulette CM.

Acta Neuropathol. 2001 Dec;102(6):621-6.

PMID:
11761723
13.

CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.

Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.

J Alzheimers Dis. 2011;27(2):377-84. doi: 10.3233/JAD-2011-110482.

PMID:
21841257
14.

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.

Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T.

J Neurol Neurosurg Psychiatry. 2010 Jun;81(6):608-10. doi: 10.1136/jnnp.2009.197483.

PMID:
20522869
15.

Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.

Yoon JH, Kim M, Moon SY, Yong SW, Hong JM.

J Neurol Sci. 2015 Aug 15;355(1-2):174-9. doi: 10.1016/j.jns.2015.06.013. Epub 2015 Jun 10.

PMID:
26076880
16.

Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.

Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, Arai H, Furukawa K.

J Neurochem. 2016 Jan;136(2):258-61. doi: 10.1111/jnc.13399. Epub 2015 Nov 11.

17.

CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease.

Atkinson A, Singleton AB, Steward A, Ince PG, Perry RH, McKeith IG, Fairbairn AF, Edwardson JA, Daly AK, Morris CM.

Pharmacogenetics. 1999 Feb;9(1):31-5.

PMID:
10208640
18.

Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism.

Brønnick K, Breitve MH, Rongve A, Aarsland D.

J Alzheimers Dis. 2016 Jun 30;53(4):1277-85. doi: 10.3233/JAD-160294.

PMID:
27372647
19.

Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.

Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, Colloby SJ, Jellinger K, Attems J.

Acta Neuropathol. 2015 May;129(5):729-48. doi: 10.1007/s00401-015-1406-3. Epub 2015 Mar 11.

PMID:
25758940
20.

TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing.

McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J.

Brain Pathol. 2016 Aug 6. doi: 10.1111/bpa.12424. [Epub ahead of print]

PMID:
27495267

Supplemental Content

Support Center